Timing of the placement is also important. The company has plenty of ways to raise that amount of capital for the quarter ahead. They’ve been raising just what they need, just when they need it to keep it minimal. The recent loan had a specific purpose to build out C suites and purchase FlaskWorks machines. Why would a Healthcare speciality HF invest right now? I’d say there’s more beneath that surface. When you look at the Q and Quarterlies the company has laid out the plan; in-licence IP from others that fits with their product and manufacturing capabilites, engage in new trials both in combination and for new indications, grow the manufacturing according to demand at time of MAA approval. I’d be willing to bet SIO has had a look at what else is coming that will need financing when announced. I don’t think that’s too hard to figure out.
Market Data 
Markets 
